These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1797 related items for PubMed ID: 25981758

  • 1. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP, TRAFFIC Study Group, TRANSPORT Study Group.
    N Engl J Med; 2015 Jul 16; 373(3):220-31. PubMed ID: 25981758
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda G, Waltz D, Wainwright CE, VX-809 TRAFFIC and TRANSPORT study groups.
    Lancet Respir Med; 2016 Aug 16; 4(8):617-626. PubMed ID: 27298017
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
    Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS.
    Lancet Respir Med; 2017 Feb 16; 5(2):107-118. PubMed ID: 28011037
    [Abstract] [Full Text] [Related]

  • 6. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
    Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS.
    N Engl J Med; 2017 Nov 23; 377(21):2013-2023. PubMed ID: 29099344
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL, VX16-445-001 Study Group.
    N Engl J Med; 2018 Oct 25; 379(17):1612-1620. PubMed ID: 30334692
    [Abstract] [Full Text] [Related]

  • 9. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM, VX16-659-101 Study Group.
    N Engl J Med; 2018 Oct 25; 379(17):1599-1611. PubMed ID: 30334693
    [Abstract] [Full Text] [Related]

  • 10. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
    McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS.
    Lancet Respir Med; 2019 Apr 25; 7(4):325-335. PubMed ID: 30686767
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
    Schwarz C, Sutharsan S, Epaud R, Klingsberg RC, Fischer R, Rowe SM, Audhya PK, Ahluwalia N, You X, Ferro TJ, Duncan ME, Bruinsma BG.
    J Cyst Fibros; 2021 Mar 25; 20(2):228-233. PubMed ID: 32586736
    [Abstract] [Full Text] [Related]

  • 15. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY, Dopfer C, Naehrlich L, Gyulumyan L, Scheuermann H, Hirtz S, Wege S, Mairbäurl H, Dorda M, Hyde R, Bagheri-Hanson A, Rueckes-Nilges C, Fischer S, Mall MA, Tümmler B.
    Am J Respir Crit Care Med; 2018 Jun 01; 197(11):1433-1442. PubMed ID: 29327948
    [Abstract] [Full Text] [Related]

  • 16. GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).
    van Koningsbruggen-Rietschel S, Conrath K, Fischer R, Sutharsan S, Kempa A, Gleiber W, Schwarz C, Hector A, Van Osselaer N, Pano A, Corveleyn S, Bwirire D, Santermans E, Muller K, Bellaire S, Van de Steen O.
    J Cyst Fibros; 2020 Mar 01; 19(2):292-298. PubMed ID: 31594690
    [Abstract] [Full Text] [Related]

  • 17. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.
    Dilokthornsakul P, Patidar M, Campbell JD.
    Value Health; 2017 Dec 01; 20(10):1329-1335. PubMed ID: 29241892
    [Abstract] [Full Text] [Related]

  • 18. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW, Murphy J, Sinha IP, Nevitt SJ.
    Cochrane Database Syst Rev; 2020 Dec 17; 12(12):CD010966. PubMed ID: 33331662
    [Abstract] [Full Text] [Related]

  • 19. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
    Murer C, Huber LC, Kurowski T, Hirt A, Robinson CA, Bürgi U, Benden C.
    Swiss Med Wkly; 2018 Dec 17; 148():w14593. PubMed ID: 29451946
    [Abstract] [Full Text] [Related]

  • 20. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, Davies JC, Lekstrom-Himes JA, Wang LT, VX11-661-101 Study Group.
    Am J Respir Crit Care Med; 2018 Jan 15; 197(2):214-224. PubMed ID: 28930490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 90.